RET

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Sun, 09/6/20 - 07:22 pm
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
Mon, 09/9/19 - 08:08 pm
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly